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Brucellosis is a zoonotic disease with a worldwide distribution that can be transmitted via intentional or
accidental aerosol exposure. In order to engineer superior vaccine strains against Brucella species for use in animals
as well as in humans, the possibility of challenge infection via aerosol needs to be considered to properly evaluate
vaccine efficacy. In this study, we assessed the use of an aerosol chamber to infect deep lung tissue of mice to elicit
systemic infections with either Brucella abortus or B. melitensis at various doses. The results reveal that B. abortus
causes a chronic infection of lung tissue in BALB/cmice and peripheral organs at low doses. In contrast,B. melitensis
infection diminishes more rapidly, and higher infectious doses are required to obtain infection rates in animals
similar to those of B. abortus. Whether this difference translates to severity of human infection remains to be
elucidated. Despite these differences, unmarked deletion mutants BAasp24 and BMasp24 consistently confer
superior protection to mice against homologous and heterologous aerosol challenge infection and should be
considered viable candidates as vaccine strains against brucellosis.
Brucellosis is a zoonosis affecting numerous species of do-
mestic animals, wildlife, and humans (13–15). Humans are
commonly infected as a result of contact with infected animals,
ingestion of contaminated animal products such as milk, milk
products, or meat, or laboratory exposure. Abattoir workers
may also acquire the disease via aerosol exposure (2, 3, 13–15,
18, 31). The Brucella species most pathogenic to humans in-
clude Brucella melitensis, B. suis, B. abortus, and B. canis, all of
which are distributed worldwide but are most common in Med-
iterranean countries, the Middle East, India, Mexico, Central
Asia, and Central and South America (3, 10, 13, 17, 22, 23).
Brucellosis has been reported to be the most common zoonotic
infection worldwide, with over 500,000 new infections reported
annually (22, 23). Human disease manifests as prolonged fe-
brile illness (undulant fever), flu-like symptoms, night sweats,
headache, depression, and arthritis, and infection can lead to
chronic illness, such as meningitis and endocarditis (2, 3, 8, 14,
22, 31).
Documented evidence of aerosol transmission of these or-
ganisms has emphasized the recent focus on the use of Brucella
as a potential bioterrorism agent (5, 20). In the 1950s, B. suis
was the first agent weaponized in the United States, and Bru-
cella has been evaluated for this purpose by several other
countries as well (3, 22). It has been estimated that as few as 10
to 100 organisms comprise an infectious aerosol dose in hu-
mans, and Brucella is therefore considered highly infectious
when it is delivered in this manner (3). As a result, B. meliten-
sis, B. abortus, and B. suis have been classified as category B
agents by the Centers for Disease Control and Prevention and
the National Institute of Allergy and Infectious Diseases (1,
22). The absence of a safe and efficacious vaccine for use in
humans underscores the concern.
In order to engineer superior vaccine strains against Brucella
species for use in animals as well as humans, the potential for
challenge infection via aerosol exposure needs to be consid-
ered to properly evaluate vaccine efficacy. Previous studies
have considered intranasal infection of mice and guinea pigs as
models for aerosol exposure (1, 2, 10, 12, 13, 18, 29). In this
study, we evaluated the kinetics of systemic infection in the
mouse model after aerosol exposure of deep lung tissue to
both B. abortus and B. melitensis in order to establish a novel
exposure route in the mouse model. This route of infection was
utilized to evaluate the protective efficacy of selected Brucella
mutants previously shown by our lab to elicit significant pro-
tection in mouse and goat models (14, 15).
MATERIALS AND METHODS
Bacteria and bacterial culture. The B. abortus 2308 and B. melitensis 16M
wild-type strains used for challenge, as well as unmarked deletion strains used for
vaccination studies, were routinely grown on tryptic soy agar (TSA) (Difco
Laboratories) at 37°C in an atmosphere containing 5% (vol/vol) CO2. Virulent B.
abortus strain S2308 was obtained from Billy Deyoe at the National Animal
Disease Center in Ames, IA. B. melitensis biovar 1 (16M) was originally obtained
from ATCC and was reisolated from an aborted goat fetus (14). Unmarked
deletion strains used in this study (BAasp24, BMasp24, BAvirB2, BMvirB2,
BAmanBA, and BMmanBA) were engineered previously and tested for sur-
vival and protective efficacy in BALB/c mice (15). All bacterial strains were
stored frozen at80°C in medium supplemented with 50% (vol/vol) glycerol and
grown on TSA for immediate use in each experiment. Bacteria were harvested
into phosphate-buffered saline (PBS) (pH 7.4; Gibco) to obtain the final con-
centration needed for each experiment, as estimated turbidometrically using a
Klett meter. Serial dilution was performed retrospectively to accurately deter-
mine the number of organisms in the inoculum. Lung, liver, and spleen samples
from mice were plated onto Farrell’s medium to select for Brucella. Farrell’s
medium is TSA supplemented with 5 mg/liter nalidixic acid, 25,000 IU/liter
bacitracin, 100 mg/liter cycloheximide, 5000 IU/liter polymyxin B sulfate, 20
mg/liter vancomycin, 100,000 IU/liter nystatin (Brucella selective supplement;
Oxoid), 10% (vol/vol) horse serum, and 2% (wt/vol) dextrose).
Kinetics of aerosol infection of Brucella in mice. The survival or persistence of
wild-type strain B. abortus 2308 or B. melitensis 16M was evaluated using groups
of 6- to 8-week-old female BALB/c mice (Jackson Laboratories) following aero-
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sol exposure via a Madison aerosol chamber (College of Engineering Shops,
University of Wisconsin, Madison) (30) to three different doses of Brucella added
to the chamber nebulizer: 5  107, 5  108, and 5  109 CFU/ml. The actual
numbers of infectious organisms inhaled by the mice at each dose were deter-
mined directly by euthanizing a group of four or five mice immediately after
removal from the chamber via carbon dioxide asphyxiation, homogenizing the
lungs in 1 ml PBS, and plating the preparations onto Farrell’s medium to
determine the number of CFU in the combined lung tissue for each mouse. For
kinetic studies, mice were euthanized at 1, 2, 4, 6, or 8 weeks postinfection. At
each time point, the lungs, liver, and spleen were collected and weighed, homog-
enized in 1 ml PBS, and serially diluted, and 200 l of each dilution was plated
onto Farrell’s medium. Recovered bacteria were enumerated to evaluate the
persistence of each strain.
Efficacy studies. The mouse model was used to evaluate the efficacies of
unmarked deletion mutants (previously shown to protect mice against virulent
Brucella by intraperitoneal [i.p.] challenge) against subsequent aerosol challenge.
Groups of four or five female 6- to 8-week-old BALB/c mice were vaccinated via
i.p. injection of 1  106 CFU/ml of unmarked deletion mutant or PBS for naı¨ve
controls. Mice were subsequently challenged with an aerosol chamber dose of
5 109 CFU/ml of the homologous wild-type strain at 20 weeks postvaccination.
Four weeks after the virulent challenge (corresponding to 24 weeks postvacci-
nation), the mice were euthanized, and the lungs, liver, and spleen were ex-
tracted, weighed, homogenized in 1 ml PBS, serially diluted, and plated onto
Farrell’s medium to measure recovery of the challenge organism.
To evaluate cross-species protection, groups of four or five female 6- to
8-week-old BALB/c mice were vaccinated with either the BAasp24 or
BMasp24 unmarked mutant strain and challenged as described above with the
heterologous wild-type strain 20 weeks postvaccination. Four weeks after the
virulent challenge, the mice were euthanized, and the challenge organisms re-
covered were enumerated as described above.
For both experiments, vaccine efficacy is described in the text as a measure of
protective immunity or units of protection (U), representing differences in bac-
terial burden in the spleen of challenge organism for naı¨ve and vaccinated mice
(log10 wild type recovered from unvaccinated mice  log10 wild type recovered
from vaccinated mice).
Statistical analysis. Data from aerosol infection kinetics and efficacy studies
were expressed as mean CFU  standard error and are presented below in
graphs as the log10 Brucella CFU recovered per organ. Culture-negative organs
were assigned a value of 4 CFU/organ, which is below the limit of detection of 5
CFU/organ. Spleen weight data from aerosol kinetics studies were plotted as the
mean spleen weight (in mg)  standard error. The statistical significance of
differences between vaccinated animals was evaluated by analysis of variance
(ANOVA) by comparing the spleen weights for a group of five naı¨ve, unvacci-
nated BALB/c control mice (data not shown) to the spleen weights for all mice
receiving the same chamber dose inoculum, followed by Dunnett’s multiple-
comparison test.
In efficacy studies vaccinated and subsequently challenged mice were com-
pared to mice receiving PBS as a vaccine control that were challenged with the
wild-type organism. The statistical significance of differences between vaccinated
animals was analyzed by ANOVA followed by Tukey’s honestly significant dif-
ference posttest comparing all groups to one another. For all ANOVAs, P values
less than 0.05 were considered statistically significant.
RESULTS
Kinetics of aerosol infection with B. abortus. Mice were
infected with three different doses of B. abortus 2308 via aero-
sol challenge to evaluate the kinetics of infection in the lungs,
livers, and spleens. Mice receiving a dose of 5  107 CFU/ml
added to the chamber nebulizer actually inhaled much less
challenge organism into the total lung tissue; the average was
determined to be 415 organisms per mouse (2.62 logs) (Fig.
1A). At this dose, lung colonization with 2308 gradually in-
creased over the first 4 weeks postchallenge and then gradually
decreased over the following 4 weeks to 90% of the maximum
value. Despite this slight decrease, colonization by the organ-
ism in the other tissues was consistent with a chronic infection.
Colonization of the liver, although barely detectable at 1 week
postchallenge, steadily increased over the first 4 weeks post-
challenge and then declined negligibly between weeks 4 and 8.
The spleens of infected mice displayed a colonization pattern
similar to that of the livers, although the total number of CFU
recovered was consistently higher. Spleen colonization in-
creased between weeks 4 and 8, consistent with a persistent
infection.
Mice receiving doses of 5  108 and 5  109 CFU/ml added
to the chamber nebulizer on average inhaled 1,266 and 34,560
organisms per mouse (3.1 and 4.54 logs), respectively (Fig. 1B
and 1C). Other than the difference in the numbers of organ-
isms inhaled and a 0.5- to 1.0-log increase in lung colonization,
the difference in the persistence of the organism in each of the
tissues evaluated was negligible.
Kinetics of aerosol infection with B. melitensis. As described
above for B. abortus, mice were infected with three different
doses of B. melitensis 16M via the aerosol route to evaluate the
kinetics of infection in the lungs, livers, and spleens. Mice
receiving a dose of 5  107 CFU/ml added to the chamber
nebulizer inhaled an average of 805 organisms per mouse (2.91
logs) (Fig. 2A). Mice receiving a dose of 5  108 CFU/ml
added to the chamber nebulizer inhaled an average of 7,988
organisms per mouse (3.9 logs) (Fig. 2B). Mice receiving a
dose of 5  109 CFU/ml added to the chamber nebulizer
inhaled an average of 12,520 organisms per mouse (4.10 logs)
(Fig. 2C). It is not clear whether the failure to record a 10-fold
increase in inhaled organisms at the highest dose was the
result of the viscosity of the inoculum (i.e., the more con-
centrated culture did not pass through the nebulizer as well
as lower doses) or the breathing patterns of the mice in the
last chamber run.
At the lowest dose, lung, liver, and spleen colonization with
16M displayed an erratic colonization pattern with large vari-
ations between mice, despite the fact that these mice received
on average a higher dose than animals infected with B. abortus.
Overall, the increased levels of colonization in all tissues (aside
from the initial lung colonization immediately after exposure)
peaked by 4 weeks after exposure, although the levels were
lower than the challenge dose. Tissue colonization followed
the same profile over the first 4 weeks, with liver and spleen
colonization subsequent to lung colonization, and reached a
peak by 4 weeks postexposure. However, in contrast to colo-
nization by B. abortus, systemic colonization of the liver and
spleen waned over the next 4 weeks, and there was a 90 to 99%
reduction in the number of CFU.
Splenomegaly induced by aerosol exposure. The coloniza-
tion profiles described above parallel those observed for i.p.
inoculations and, except for lung involvement, confirm that
introduction via aerosol exposure results in a similar course of
systemic infection. As an alternative measure of disease in the
mice, spleen weights were also recorded to observe splenomeg-
aly patterns. Mice infected with B. abortus did not have signif-
icant splenomegaly until 6 weeks postinfection with the 5 108
and 5  109 CFU/ml chamber doses or until 8 weeks postin-
fection with the lower dose (5  107 CFU/ml) (Fig. 3A). This
inflammation correlated with the levels of bacteria in the
spleen, which began to peak or plateau at 4 to 6 weeks postin-
fection depending upon the dose. This pattern is analogous to
that observed following i.p. inoculation, where splenomegaly
mirrored spleen colonization but was delayed.
Mice infected with the lowest chamber dose of 16M did not
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display significant splenomegaly, which correlated with the er-
ratic infection observed (Fig. 3B). Mice infected at the 5 
108-CFU/ml chamber dose presented with significant spleno-
megaly 6 weeks postinfection, subsequent to the peak bacterial
load observed in the spleen. Mice infected at the highest cham-
ber dose, 5  109 CFU/ml, exhibited splenomegaly earlier, at
4 weeks postinfection, paralleling the increased spleen coloni-
zation evident at 1 week postchallenge.
FIG. 1. Kinetics of clearance of B. abortus 2308 from BALB/c mice. Four or five female BALB/c mice were infected with aerosolized 2308 in a
Madison aerosol chamber using three different chamber doses, 5  107 CFU/ml (A), 5  108 CFU/ml (B), or 5  109 CFU/ml (C). The initial lung
colonization was evaluated immediately after challenge to determine the quantity of Brucella inhaled for each chamber dose. Mice were euthanized at
1, 2, 4, 6, or 8 weeks postchallenge to determine the numbers of Brucella persisting in the lungs, livers, and spleens. The recovery of organisms is plotted
as the total CFU/organ (means  standard errors). The solid line at 0.7 log represents the lower limit of detection, which is 5 CFU.
VOL. 75, 2007 AEROSOL BRUCELLOSIS 4925
FIG. 2. Kinetics of clearance of B. melitensis 16M from BALB/c mice. Four or five female BALB/c mice were infected with aerosolized 16M in a
Madison aerosol chamber using three different chamber doses, 5  107 CFU/ml (A), 5  108 CFU/ml (B), or 5  109 CFU/ml (C). The initial lung
colonization was determined immediately after challenge to determine the quantity of Brucella inhaled for each chamber dose. Mice were euthanized at
1, 2, 4, 6, or 8 weeks postchallenge to determine the numbers of Brucella persisting in the lungs, livers, and spleens. The recovery of organisms is plotted
as the total CFU/organ (means  standard errors). The solid line at 0.7 log represents the lower limit of detection, which is 5 CFU.
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Protective efficacy against homologous B. abortus aerosol
challenge. To evaluate the vaccine potential of selected B.
abortus unmarked mutants BAasp24, BAvirB2, and
BAmanBA against virulent aerosol infection, the level of
protection provided against wild-type colonization was as-
sessed. Protective efficacy was expressed as a value relative
to the nonvaccinated controls challenged with the wild type
at each time point, which was obtained by subtracting the
mean number of CFU/organ recovered from vaccinated
mice from the mean number of CFU/organ recovered from
age-matched nonvaccinated aerosol-challenged controls.
The highest chamber dose, 5  109 CFU/ml, was chosen for
the challenge inoculum, and mice were challenged with the
wild type (S2308) 20 weeks after i.p. vaccination with each
mutant. Colonization by the wild type was determined 4
weeks after challenge (corresponding to 24 weeks postvac-
cination) in the spleen, liver, and lungs.
As described previously for i.p. challenge and as described
above, the spleens of mice typically have the highest bacterial
burden and spleen tissue is the most useful tissue for monitor-
ing Brucella infection. In these experiments the bacterial bur-
den in the spleen following aerosol challenge was reduced 2.02
U by vaccination with BAasp24 and by 0.86 U by vaccination
with BAvirB2 relative to the burden in naı¨ve mice (P  0.001
and P  0.05, respectively) (Fig. 4C). In contrast, the rough
BAmanBA mutant was unable to elicit significant protective
immunity relative to the immunity of naı¨ve mice (0.06 U; P
0.05).
At 24 weeks postvaccination, less protection was observed in
the lungs of mice vaccinated with BAasp24 (0.83 U) and
BAvirB2 (0.43 U), although the protection was significantly
greater than that observed for naı¨ve controls (P 0.001 and P
0.05, respectively) (Fig. 4A). The rough mutant, BAmanBA,
protected mouse lungs to a lesser degree (0.35 U, which was not
significant).
Despite the large size of the liver, the colonization was 2 logs
less than that observed in either the spleen or lung, and al-
though the total recovery of wild-type organisms from livers
was reduced by an average of 1.04 U, there were too few
animals to provide statistical significance (Fig. 4B). Further-
more, the variation between mice in the BAasp24-vaccinated
group was substantial, possibly masking the degree of protec-
tion afforded in the liver, since for two of five mice no chal-
lenge organisms were recovered from the liver. No protection
was evident in BAvirB2- or BAmanBA-vaccinated animals
(0.03 and 0.44 U of protection, respectively).
Protective efficacy against homologous B. melitensis aerosol
challenge. Mice were vaccinated i.p. with B. melitensis unmarked
deletion strains BMasp24, BMvirB2, and BMmanBA and
allowed to rest for 20 weeks prior to aerosol challenge with 16M.
The highest chamber dose, 5 109 CFU/ml 16M, was chosen for
FIG. 3. Evaluation of splenomegaly induced by Brucella aerosol challenge. Spleen weights of mice infected in B. abortus (A) and B. melitensis
(B) aerosol kinetics studies were recorded as a measure of splenomegaly induced by the infection. The data are the averages and standard errors
for all mice in a treatment group. Statistical significance was determined by ANOVA, followed by Dunnett’s multiple-comparison test comparing
the spleen weights of a group of five unchallenged BALB/c mice to the spleen weights of all mice receiving the same chamber inoculum dose. The
dotted line represents the average spleen weight of uninfected mice (96 mg). One asterisk, P  0.05; two asterisks, P  0.01.
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the challenge inoculum. The mice were euthanized 4 weeks post-
challenge (corresponding to 24 weeks postvaccination).
Spleens of mice were highly protected against aerosol 16M
challenge by BMasp24 (3.99 U), and for three of five mice
no recoverable 16M was detected in the spleen (P  0.001)
(Fig. 5C). BMmanBA-vaccinated mice were also significantly
protected compared to naı¨ve controls (1.59 U) (P  0.05).
BMvirB2 was unable to elicit significant protective immunity
in the spleens (0.92 U; P  0.05).
Lung colonization in mice indicated that there were much
FIG. 4. Evaluation of the efficacy of vaccination against B. abortus aerosol challenge. Groups of four or five female 6- to 8-week-old BALB/c mice
were vaccinated via i.p. injection of 1  106 CFU/ml of unmarked deletion mutant BAasp24, BAvirB2, BAmanBA, or BMasp24 or PBS for naı¨ve
controls. Mice were subsequently challenged with an aerosol chamber dose of 5 109 CFU/ml B. abortus 2308 at 20 weeks postvaccination (heterologous
challenge for BMasp24). Four weeks after the virulent challenge, the mice were euthanized, and lungs (A), livers (B), and spleens (C) were extracted
to measure the recovery of the challenge organisms. Data are expressed as the log10 recovery of 2308 from the entire organ, and the results for individual
mice in each treatment group are shown. The solid line at 0.7 log represents the lower limit of detection, which is5 CFU. For comparisons with naı¨ve
control animals using ANOVA with Tukey’s honestly significant difference posttest, one asterisk indicates that the P value is 0.05 and two asterisks
indicates that the P value is 0.01.
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lower levels of protection against virulent 16M challenge by
vaccination with BMasp24 (1.72 U) and BMvirB2 (1.22 U),
but the levels were significantly greater than those for naı¨ve
controls (P  0.001 for both) (Fig. 5A). The rough mutant,
BMmanBA, protected mouse lungs to a lesser degree (0.25
U, which was not significant).
In contrast to B. abortus colonization, B. melitensis reached
higher levels in the tissues, providing statistically significant re-
sults. As a result, significant levels of protection against 16M
aerosol infection were observed after vaccination with BMasp24
(2.78 U), and three of five mice had no recoverable 16M in their
livers (P  0.001) (Fig. 5B). The livers of mice vaccinated with
FIG. 5. Evaluation of the efficacy of vaccination against B. melitensis aerosol challenge. Groups of four or five female 6- to 8-week-old BALB/c
mice were vaccinated via i.p. injection of 1  106 CFU/ml of unmarked deletion mutant BMasp24, BMvirB2, BMmanBA, or BAasp24 or PBS
in naı¨ve controls. Mice were subsequently challenged with an aerosol chamber dose of 5  109 CFU/ml B. melitensis 16M at 20 weeks
postvaccination (heterologous challenge for BAasp24). Four weeks after the virulent challenge, the mice were euthanized, and lungs (A), livers
(B), and spleens (C) were extracted to measure recovery of the challenge organism. Data are expressed as the log10 recovery of 16M from the entire
organ, and the results for individual mice in each treatment group are shown. The solid line at 0.7 log represents the lower limit of detection, which
is 5 CFU. For comparisons with naı¨ve control animals using ANOVA with Tukey’s honestly significant difference posttest, one asterisk indicates
that the P value is 0.05 and two asterisks indicates that the P value is 0.01.
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BMmanBA also exhibited significant protection compared to
naı¨ve controls (1.83U) (P 0.001). BMvirB2 also protected the
livers (0.51 U, which was not significant).
Protective efficacy against heterologous aerosol challenge
with B. abortus and B. melitensis. Heterologous challenges of
vaccinated mice were performed to evaluate if the highly protec-
tive mutants, BAasp24 and BMasp24, elicit cross-species pro-
tection. When mice were challenged with 2308, the BMasp24
mutant significantly protected mouse lungs (1.42 U) (P  0.001)
and spleens (3.13 U) (P  0.01) (Fig. 4A and 4C). In this case,
organisms were cultured from only two of four mouse spleens.
The livers were not significantly protected, although there was an
evident reduction (0.96 U) (Fig. 4B). When mice were challenged
with 16M, the BAasp24 mutant significantly protected the lungs
(1.51 U) (Fig. 5A) (P  0.001). In the liver, mice were protected
(2.65 U), and the challenge organism was not recovered from
three of five mice (Fig. 5B) (P 0.001). The spleens of mice were
significantly protected (4.25 U), and the challenge organism was
not recovered from three of five mice (Fig. 5C) (P  0.001).
DISCUSSION
Human brucellosis is often associated with aerosol transmis-
sion and is therefore considered a biowarfare threat. Protec-
tion afforded by novel Brucella vaccine strains should therefore
consider challenge via inhalation of infectious organism to
evaluate vaccine efficacy. Aerosol chambers have been success-
fully used to study infections with several different organisms,
including Mycobacterium tuberculosis, Bacillus anthracis, and
Coxiella burnetti in mice and guinea pigs (11, 16, 25–27). Aero-
sol exposure has also been utilized previously to infect rhesus
macaques with B. melitensis, but this is the first evaluation of
aerosol infection in mice, which have been widely used to
model human infections (17).
In this study, a Madison aerosol chamber was utilized to
infect groups of mice with B. abortus or B. melitensis. Use of the
Madison chamber leads to infection of deep lung tissue, spe-
cifically the delivery of droplet nuclei to alveolar spaces, as
might be experienced as a result of inhalation during aerosol
exposure (26, 30). Ranges of inoculum doses were evaluated to
determine differences in the levels of infectivity between the
two bacterial species, as well as to establish the kinetics of
systemic infection. Under these controlled conditions in an
enclosed environment, it was found that as little as a 5-min
exposure to 5 107 CFU/ml is sufficient to cause infection in
the lungs and systemically in mice. However, consistent results
for B. melitensis required exposure to doses that were 10 to 100
times greater. Although organisms were detected on the fur of
animals using cotton swabs, the recovery data suggested that
the levels were in the range from 100 to 1,000 organisms per
mouse, which is well below the oral dose necessary for infec-
tion (12).
It has been previously reported that variation in the Brucella
exposure dose in primates alters the kinetics of trafficking to
peripheral organs (18). This effect was also evident here for the
murine model after aerosol inoculation. B. abortus infection of
mice via the aerosol route results in immediate colonization of
lung tissue that is sustained or increases over time, indicating a
capacity to replicate within the lung. Bacterial colonization of
livers and spleens was delayed as long as 2 weeks before no-
ticeable colonization in these organs became evident, and this
colonization occurred without diminution within the lungs,
consistent with replication of the organism. B. melitensis infec-
tions of mice (including lung tissue) appeared to be variable
early in infection at lower doses compared to B. abortus infec-
tions. Significant systemic colonization of spleens and livers
was evident as early as 1 week postinfection only in the group
receiving the highest dose and occurred 2 weeks postinfection
with lower challenge doses.
Comparison of the durations of Brucella infections in mice
exposed by the i.p. and intravenous routes also revealed a more
persistent and chronic infection with B. abortus than with B.
melitensis (6, 7, 9, 15, 21). Although the present studies con-
sidered time points up to only 8 weeks postinfection, a similar
trend was observed with the aerosol exposure described here.
It may be concluded that B. abortus infection via the aerosol
route elicits a persistent and relatively constant bacteremia in
BALB/c mice, requiring a much lower inoculum dose than that
required for B. melitensis. Persistence in the lung and the
chronic nature of the infection appear to extend the period of
optimum systemic colonization for both organisms.
Splenomegaly is a well-known clinical manifestation associ-
ated with Brucella infection that correlates with increased num-
bers of mononuclear cells and appears to be dependent on the
bacterial burden (9, 17–19, 28). Splenomegaly was evident af-
ter aerosol exposure with both B. abortus, with which spleno-
megaly was delayed until approximately 6 weeks postexposure,
and B. melitensis, with which splenomegaly was evident earlier
at 4 weeks postexposure. Overall, the gross size of the spleens
was not as great as the gross sizes observed when other routes
of infection were used, although splenomegaly remained a
significant marker of disease in these mice (4, 9, 28).
The highest chamber dose, 5  109 CFU/ml, was chosen as
the challenge inoculum in efficacy trials. This dose closely mim-
ics the doses used in previous efficacy studies for the same
vaccine strains when mice were challenged with 1  104 CFU/
mouse via the i.p. route (15). The mice in the present experi-
ments received 3.3  104 CFU 2308/mouse or 1.3  104 CFU
16M/mouse via the aerosol route, and therefore the levels of
protection afforded, particularly in the spleens, could be com-
pared for the two studies. It is important to note, however, that
in previous studies mice were euthanized 1 week postchal-
lenge, whereas here they were euthanized 4 weeks postchal-
lenge. The 4-week time point was chosen to allow adequate
infection of the peripheral organs in order to properly evaluate
efficacy.
It is interesting to observe that, particularly for B. abortus
challenges, the protection afforded to the lungs against infec-
tion is not as marked (although for three vaccine strains it is
significant) as the protection afforded to the spleen. There are
several possible explanations for this observation. The first and
most obvious possible explanation is the use of the i.p. route of
vaccination. Although not known with certainty, organisms are
not expected to traffic to lung tissue, and therefore the lungs
may not elicit the same immune response upon challenge in-
fection that would be expected if they were primed by vacci-
nation. Alternatively, it is possible that a lack or diminishment
of an inflammatory response in the lungs masks the efficacy of
vaccination. It has been previously demonstrated that lungs of
mice inoculated intranasally with 16M, although colonized, do
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not show substantial histologic changes associated with the
infection or an indication of inflammatory responses (18). In
addition, rhesus macaques infected with 16M via the aerosol
route did not develop significant pathological lesions in lung
tissues (17). Epithelial cells of the lungs have been shown to
control inflammation and immune responses in the airways
and alveoli (24). Protection against aerosol challenge may
therefore be enhanced if the vaccine strain itself is delivered
via mucosal routes, including oral or nasal delivery.
Another possible explanation for the persistence of B. abor-
tus in the lung tissue, even in vaccinated mice, is that B. abortus
challenge was performed with a dose that overwhelmed the
immune response. Particularly for B. abortus, we demonstrated
that persistent infection also resulted from aerosol exposure at
doses that were 10- to 100-fold reduced, and therefore lower
doses could be used for challenge.
In this study, we established a novel infection model of
Brucella infection in BALB/c mice that parallels natural
exposure. We showed that consistent B. abortus aerosol in-
fection of mice is possible using as few as 4  102 organisms
per animal, whereas infection with B. melitensis requires
between 8  103 and 1  104 organisms per mouse to be
consistent. It was also demonstrated that the BAasp24 and
BMasp24 unmarked deletion mutants, which have been
previously shown to elicit superior protection against i.p.
challenge, also evoke significant protection against B. abor-
tus and B. melitensis homologous and heterologous aerosol
challenges in lungs, livers, and spleens. The BMasp24 mu-
tant was also previously tested for safety in pregnant goats
and did not cause abortion (14). As such, the asp24 dele-
tion mutants remain excellent candidates for further evalu-
ation due to their protective ability, while they remain safe
for pregnant animals. Future studies should include vacci-
nation of mice intranasally to enhance mucosal immunity for
improvement of memory responses against aerosol infection
with Brucella.
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